{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:55:48Z","timestamp":1777420548885,"version":"3.51.4"},"reference-count":29,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T00:00:00Z","timestamp":1529625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:p>Objective: To review efficacy and safety of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide for type 2 diabetes (T2D). Data Sources: A literature search of PubMed\/MEDLINE and EMBASE using the term semaglutide was completed through April 2018. A search of clinicaltrials.gov was also conducted. Study Selection and Data Extraction: English-language studies assessing the efficacy and\/or safety of semaglutide were evaluated. Data Synthesis: Semaglutide is a newly approved GLP-1 RA for the treatment of T2D. Administered once weekly at a dose of 0.5 or 1 mg, it has been compared with placebo, sitagliptin, insulin glargine, a combination of oral antidiabetic therapies, and 2 GLP-1 RAs, exenatide ER and dulaglutide, and demonstrated greater efficacy compared with these therapies. Published data from studies ranging from 30 to 104 weeks duration demonstrate efficacy with decreases in hemoglobin A1C (A1C) ranging from 1.1% to 2.2%. Studies show reductions in weight from 1.4 to 6.5 kg. Semaglutide demonstrated a reduction in the composite outcome of cardiovascular (CV) death, nonfatal myocardial infarction, or nonfatal stroke compared with placebo in patients at high risk of CV events (hazard ratio = 0.74; P = 0.02). Common adverse effects include nausea, vomiting, and diarrhea as seen with other GLP-1 RAs. Relevance to Patient Care and Clinical Practice: Semaglutide represents an attractive GLP-1 RA considering its A1C and weight reduction. It provides patient convenience and high patient satisfaction. Conclusions: Semaglutide is an appealing option for the treatment of T2D as a once-weekly GLP-1 RA with established glycemic, CV, and weight benefits.<\/jats:p>","DOI":"10.1177\/1060028018784583","type":"journal-article","created":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T05:49:22Z","timestamp":1529646562000},"page":"1224-1232","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes"],"prefix":"10.1177","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4355-8824","authenticated-orcid":false,"given":"Rhianna M.","family":"Tuchscherer","sequence":"first","affiliation":[{"name":"University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela M.","family":"Thompson","sequence":"additional","affiliation":[{"name":"University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer M.","family":"Trujillo","sequence":"additional","affiliation":[{"name":"University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,6,22]]},"reference":[{"key":"bibr1-1060028018784583","unstructured":"International Diabetes Federation. IDF Diabtes Atlas. 8th ed. Brussels, Belgium: International Diabetes Federation; 2017. http:\/\/www.idf.org\/diabetesatlas. Accessed March 21, 2018."},{"key":"bibr2-1060028018784583","volume-title":"Diabetes 2017 Report Card","author":"Centers for Disease Control and Prevention","year":"2018"},{"key":"bibr3-1060028018784583","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-S009"},{"key":"bibr4-1060028018784583","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-S010"},{"key":"bibr5-1060028018784583","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"bibr6-1060028018784583","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"bibr7-1060028018784583","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"bibr8-1060028018784583","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-S008"},{"key":"bibr9-1060028018784583","doi-asserted-by":"publisher","DOI":"10.4158\/CS-2017-0153"},{"key":"bibr10-1060028018784583","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441"},{"key":"bibr11-1060028018784583","doi-asserted-by":"publisher","DOI":"10.1177\/2042018814559725"},{"key":"bibr12-1060028018784583","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12596"},{"key":"bibr13-1060028018784583","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00726"},{"key":"bibr14-1060028018784583","unstructured":"Ozempic [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2017."},{"key":"bibr15-1060028018784583","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.443"},{"key":"bibr16-1060028018784583","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30013-X"},{"key":"bibr17-1060028018784583","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"bibr18-1060028018784583","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30092-X"},{"key":"bibr19-1060028018784583","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13082"},{"key":"bibr20-1060028018784583","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0417"},{"key":"bibr21-1060028018784583","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30085-2"},{"key":"bibr22-1060028018784583","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30024-X"},{"key":"bibr23-1060028018784583","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13218"},{"key":"bibr24-1060028018784583","unstructured":"Medicine Matters. A quick guide to the SUSTAIN trials. https:\/\/diabetes.medicinematters.com\/semaglutide\/type-2-diabetes\/a-quick-guide-to-the-sustain-trials\/12206922. Accessed March 6, 2018."},{"key":"bibr25-1060028018784583","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Ozempic NDA 209637 approval letter. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2017\/209637s000ltr.pdf. Published December 5, 2017. Accessed March 20, 2018."},{"key":"bibr26-1060028018784583","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.08.481"},{"key":"bibr27-1060028018784583","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12932"},{"key":"bibr28-1060028018784583","unstructured":"DiGrande S. Novo Nordisk announces phase 3a trial results for oral semaglutide. http:\/\/www.ajmc.com\/newsroom\/novo-nordisk-announces-phase-3a-trial-results-for-oral-semaglutide. Published February 26, 2018. Accessed March 26, 2018."},{"key":"bibr29-1060028018784583","unstructured":"Novo Nordisk. Novo Nordisk successfully completes the first phase 3a trial, PIONEER 1, with oral semaglutide. https:\/\/globenewswire.com\/news-release\/2018\/02\/22\/1379640\/0\/en\/Novo-Nordisk-successfully-completes-the-first-phase-3a-trial-PIONEER-1-with-oral-semaglutide.html. Published February 22, 2018. Accessed April 11, 2018."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028018784583","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028018784583","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028018784583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:31Z","timestamp":1777374871000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028018784583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,22]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1177\/1060028018784583"],"URL":"https:\/\/doi.org\/10.1177\/1060028018784583","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,22]]}}}